Emergence of India as a Global Health Provider and its Impact on Pharmaceutical Education

14^th International Conference on Pharmaceutical Education and Practice

October 28, 2022 | Webinar

T. R. Bhardwaj

Baddi University of Emerging Sciences & Technology, India

Keynote: Biomedical & Pharmaceutical Sciences

Abstract :

India has emerged as global health provider, having expertise in manufacturing of generics. This drug industry flourished after the passage of the Drug Price Competition and Patent Term Restoration Act of 1984. Fifty years later, the generic drug industry has achieved remarkable success in getting affordable medicines to patients. The generic products typically cost 50 to 70 percent less than their brand-name counterpartswhile meeting the very same standards for safety, quality, and effectiveness as innovator drugs. Global pharmaceutical market is undergoing rapid transformation. The products manufactured by the Indian pharmaceutical industry can be broadly classified into active pharmaceutical ingredients and formulations. India is one among the largest API manufacturers in terms of volume and value. Out of the total number of pharmaceutical manufacturers, about 77% produce formulations and remaining 23% manufacture bulk drugs. In 2001, CIPLA introduced the world first ever recommended fixed dose combination (Stavudine + Lamivudine + Neviropine) to fight AIDS. It was made available at less than $1 per day compared to over $12,000 per patient per year prevailing in most countries. The UN Secretary-General, Antonio Guterres has applauded India for supplying COVID-19 doses to nations around the world to combat the catastrophic global health crisis. India has played a major role in ensuring a global vaccination to fight the pandemic. Guterres said, “I would like to say how much we count on India, I mean, India has one of the most advanced pharmaceutical industries. India played a very important role in the production of generics for use that was a very important element of democratisation all over the world”. Taking into consideration the above mentioned India’s potential and capabilities with respect to global healthcare, opportunities, challenges and their impacts on pharmaceutical education will be discussed.

Biography :

Prof. T. R. Bhardwaj is renowned pharmaceutical academician, scientist and presently working as Advisor to Chancellor (Former Vice Chancellor), Baddi University of Emerging Sciences & Technology, Baddi. He has also been Dean, School of Pharmacy and Emerging Sciences since September, 2014. Prof. Bhardwaj has obtained M. Pharm. and Ph.D. degrees from University Institute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh and served his alma matter for around 32 years under various capacities such as Dean-Faculty of Pharmaceutical Sciences, Chairman-UIPS. He has also been International Research Fellow, SRI-International (Formerly Stanford Research Institute), California, USA from August, 1988 to January, 1996 (around 4 years). Prof. Bhardwaj has 17 patents including 9 US patents and more than 200 publications in reputed International/National journals. He has guided 15 Ph.D. and 90 M. Pharm. Students. Dr. Bhardwaj is recipient of GP Srivastava Memorial Award, Association of Pharmaceutical Teachers of India, December, 2017, Teacher of Excellence Award, Golden Jubilee Celebrations, APTICON 2016 and recently has received ET (Economic Times) Inspiring Leaders Award in Education in December, 2021.